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Abstract. In this paper, we introduce a model for drug delivery optimisation in a chronotherapeu-
tics framework. We present a pharmacokinetics and pharmacodynamics model for oxaliplatin and 5-
Fluorouracil, a classic therapeutic association in the treatment of colorectal cancer. We derive the phar-
macokinetics model using law of mass action and enzyme kinetics. We design an age-structured cell cycle
PDE model with drug damage and repair phases to account for the effect of the drugs on proliferating cell
populations, with different parameters for healthy and cancer cell populations focused on their different syn-
chronisation responses to circadian clock triggering. Our goal is to minimise the growth rate of cancerous
cells while maintaining the growth rate of healthy cells above a given toxicity threshold. We numerically
optimise the drug delivery schedules under our model and obtain theoretically efficient infusion schemes
in a chronotherapeutics framework, with as well as without circadian clock involvement in the molecular
pharmacological model.
Keywords and phrases: Cell population dynamics, Age-structured models, Cell division cycle, Phar-
macological models, Drug delivery optimisation
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1. Introduction
Optimising drug delivery in the general circulation targeted towards cancer cell populations, but inevitably reaching
also proliferating healthy cell populations imposes to design optimised drug infusion algorithms in a dynamic way,
i.e., controlling the growth of both populations simultaneously by the action of the drugs in use, wanted for cancer
cells, and unwanted for toxic side effects on healthy cells.
Towards this goal, we design models and methods, with optional representation of circadian clock control on
proliferation in both populations, according to three axes [17, 18]: a) representing the oncologist’s main weapons,
drugs, and their fates in the organism by molecular-based pharmacokinetic-pharmacodynamic equations; b) rep-
resenting the cell populations under attack by drugs, and their proliferation dynamics, including in the models
molecular and functional targets for the drugs at stake, by physiologically structured equations; c) using numerical
algorithms, optimising drug delivery under different constraints at the whole organism level, representing impacts
of multiple drugs with different targets on cell populations.
In the present study, two molecular pharmacological ODE models, one for oxaliplatin, and one for 5-
Fluorouracil, have been designed, using law of mass action and enzyme kinetics, to describe the fate of these
two cytotoxic drugs in the organism. An age-structured PDE cell population model has been designed with drug
control targets to represent the effects of oxaliplatin and 5-Fluorouracil on the cell cycle in proliferating cell pop-
ulations. The models for proliferating cell population dynamics involve possible physiological fixed (i.e., out of
reach of therapeutic influence, but of potential use by adapting drug delivery to it) circadian clock control, and
varying drug control to be optimised, connected or not with pharmacological models.
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Concentrations of drugs, represented by outputs of ODEs, are assumed to be homogeneous in the cell popula-
tions under attack by cytotoxic drugs. The possibility to describe the effects of other drugs, cytostatic (including in
this category anti-angiogenic drugs, considered as acting on the G1 phase, choking its entries and slowing it down),
is also presented, but not put in pharmacokinetic equations and actual simulations in this study, that is focused on
the combination of 5-FU and oxaliplatin, a classic therapeutic association in the treatment of colorectal cancer.
We then set conditions to numerically solve drug delivery optimisation problems (maximisation of cancer cell
kill under the constraint of preserving healthy cells over a tolerability threshold) by considering a trade-off between
therapeutic and toxic effects. The observed effects on proliferation are growth exponents, i.e., first eigenvalues of
the linear PDE systems, in the two populations, healthy and cancer. The solutions to an optimisation problem
taking into account circadian clock control are presented as best delivery time schedules for the two drugs used in
combined treatments, to be implemented in programmable delivery pumps in the clinic.
2. Molecular pharmacokinetics-pharmacodynamics
We represent drug fate in the organism by physiologically based pharmacokinetic-pharmacodynamic (PK-PD)
ODEs for drug concentrations. Drug effects, outputs of the PK-PD system, will later be considered as control
inputs in a physiologically structured cell population dynamic model representing cancer or healthy tissue prolif-
eration with prescribed targets (see Section 3). In this Section, we consider two cytotoxic drugs, oxaliplatin and
5-fluorouracil, that act on cells by killing them unless they undergo repair, and a cytostatic drug, assumed to exert
a blocking action at phase transitions of the cell cycle without inducing cell death.
Drugs are described by concentrations, from their infusion in the circulation, which is represented by infusion
flows assumed to be externally controlled by programmable pumps, until their action at the cell level. Whenever
relevant, physiological control of biological mechanisms by circadian clocks is represented here by cosine-like
curves - in the absence of better identified physiological gating functions - describing gate opening at transitions
between cell cycle phases (0: gate closed; between 0 and 1: gate opening).
2.1. The oxaliplatin model
2.1.1. Oxaliplatin pharmacodynamics: impact on the cell cycle
Oxaliplatin is an anticancer drug that has been in use for more than 12 years now in the treatment of colorectal
cancer. It exerts its action on cells by creating irreversible oxaliplatin-DNA adducts that subsequently yield double-
stranded breaks in the DNA. Although it has been shown to induce apoptosis [31] in a manner that does not show
major dependency on cell cycle phases (with the restriction that of course the DNA is always more exposed, and
thus more sensitive to oxaliplatin insults, in S-phase), other studies have shown that its main effect on cancer cells
was likely to be mostly active by arresting the cell division cycle at the G2/M, and to a lesser extent, at the G1/S
transitions [81, 82], effects on apoptosis occurring only after a prolonged exposure time. In the sequel, we shall
assess these two main actions, both induced by DNA damage. The effect on death rates will be assumed to be
directly proportional to the damage induced to the DNA, whereas the effect on phase transitions, physiologically
due mainly to p53 (not represented as such in this study), will be represented by a variable delay due to cells under
repair, that will be represented by a specific subpopulation appended to each one of the main phases G1 and S G2.
2.1.2. Oxaliplatin PK-PD: from infusion until DNA damage
The PK-PD model for oxaliplatin runs as follows
8
>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>:
dR
dt
= [xLOHP + cl +lK]R+
i(t)
VLOHP
dK
dt
= lRK +µK(K0  K)
dC
dt
= VGST
CG2
K2GST +G2
  kDNACF +xLOHPR
dF
dt
= kDNACF +µF(Fo F)
dG
dt
= VGST
CG2
K2GST +G2
+µG(G0  G)
(2.1)
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with G0(t) = G0 BASE
⇢
1+d cos
2p(t  jGSH)
24
 
and K0(t) = K0 BASE
⇢
1+ e cos
2p(t  jPLP)
24
 
, accounting for circadian tuning (if d 6= 0,e 6= 0) of equilibrium
values for tissue reduced glutathione (GSH) G0 and plasma protein (PLP) K0 concentrations.
The variables represented are concentrations, either in blood, or in tissues for:
R : Plasma oxaliplatin, with source term a continuous infusion flow i(t)
K : Plasma proteins, with equilibrium value K0 (circadian-tuned if e 6= 0)
C : Active tissue oxaliplatin (Pt4+ ion)
F : Free DNA, with equilibrium value F0: the target of the drug, that establishes DNA adducts by disulphur
bridges with it, later creating double strand breaks
G : Reduced glutathione (GSH), tissue shield against DNA damage induced by oxaliplatin, with equilibrium
value G0 (circadian-tuned if d 6= 0).
A simulation of the model behaviour under square wave drug infusion flow of oxaliplatin following a circadian
rhythm is shown on Fig. 1.
FIGURE 1. Behaviour of the two systems protecting the cells against oxaliplatin. Upper track:
oscillations of plasma proteins in the presence of infused plasma oxaliplatin (4 consecutive days
of chemotherapy followed by 10 days of recovery); lower track: oscillations of the concentra-
tions of cellular reduced glutathione in presence of Pt4+ ion, active intracellular metabolite of
oxaliplatin. Decaying track: modelled apoptosis effect of oxaliplatin; in the absence of repair,
the density of free DNA decreases in the mean, leading cells to death. The parameters used in
these simulations (see Section 4.4 for details) have been chosen to produce expected effects, and
have not been experimentally identified.
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The features of the model are: irreversible binding of oxaliplatin to plasma proteins, synthesized in the liver;
simultaneous attack in the intracellular medium of free (unbound) DNA, the drug target, and reduced glutathione,
that thus acts as a competitive target of oxaliplatin, shielding the DNA from oxaliplatin; continuous synthesis of
reduced glutathione; possible return to equilibrium value of DNA obtained by excision repair enzymes. Apart from
blood pharmacokinetic constants that are easily accessible, other parameters have been evaluated so as to produce
likely behaviour for the drug in tissues.
When circadian rhythms are considered relevant (i.e., among teams who practice anticancer circadian
chronotherapy, cf. [33, 34, 47–50, 52, 53]), peak phases jPLP and jGSH for tuned values K0 and G0 are fixed
according to laboratory or clinical published data [55, 78] adapted to human organisms (when observations were
performed on mice, it was assumed that 0 Hour After Light Onset (HALO) = 8 h, local time, and that Humans,
contrary to mice, are diurnal animals). In the simulations presented, care was not taken to optimise drug delivery
according to a clinically fixed circadian schedule, since optimisation will be performed freely later, using numerical
algorithms and with no a priori knowledge on optimal delivery time schedules. Only the parameters of circadian
physiological control functions for the cell division cycle and for the metabolism of the considered drugs will be
fixed based on such laboratory or clinical data. Note that in this physiologically based model, circadian rhythms
are not mandatory in the pharmacological model and can be neglected by setting d = e = 0 (and z = h = 0 in the
FU model below) if they are considered as irrelevant. The idea to introduce them (optionally in our setting) in the
pharmacological model comes from previous collaborative works with a team dealing with cancer chronotherapy,
Francis Lévi’s at Paul-Brousse Hospital in Villejuif, France. However, even though it is possible to neglect these
chronopharmacological effects, it is essential to represent differences between healthy and tumour cell populations,
and these are based in our model on a difference between physiologically fast and pathologically slow responses
to circadian clock stimuli in the two populations, respectively healthy and cancer. This point will be discussed in
the conclusion.
2.2. The 5-FU model
2.2.1. 5-FU pharmacodynamics and the cell division cycle
The pharmacodynamics of 5-FU is complex and multiply-targeted, as shown, e.g., in [56], resulting in non viable
modifications of the RNA and of the DNA, but most of all in thymidylate synthase inhibition. We will consider
here only its effects on its main target, thymidylate synthase, an enzyme that is essential in DNA duplication and
S-phase specific. In the same way as direct damage to the DNA was considered as proportional to added cell death,
we will assume here that thymidylate synthase degradation is proportional to 5-FU-induced cell death.
2.2.2. 5-FU PK-PD: from infusion to intracellular damage
As in the previous section (2.1) for oxaliplatin, the PK-PD of the cytotoxic drug 5-fluorouracil (5-FU) is repre-
sented by a system of ODEs, controlled by a continuous infusion flow j(t), with the help of a continuous flow
k(t) of folinic acid, a.k.a. leucovorin, a natural compound of the folate family, that stabilises the complex formed
by FdUMP with its target thymidylate synthase (TS) [56]. Also for 5-FU have been experimentally evidenced
circadian variations of the target TS and of the main enzyme responsible for drug catabolism, namely dihydropy-
rimydine dehydrogenase (DPD), such catabolism being processed mainly (80%) in the liver [56], which has been
considered here as a filter on the general circulation. On entering into a cell, the active form of 5-FU, FdUMP,
may be effluxed out of the cell by an ABC transporter [65, 73], before reaching its target, a known mechanism of
3
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resistance to 5-FU [65]. 8
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>:
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  lDPD
P
mDPD +P
+
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=
a
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P
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=
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dt
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dS
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= k1US+ k 1B+µT S(S0  S)
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= k1US  k 1B  k4BL
dT
dt
= k4BL  vT T
(2.2)
with S0(t) = S0 BASE
⇢
1+z cos
2p(t  jT S)
24
 
and lDPD(t) = lDPD BASE
⇢
1+h cos
2p(t  jDPD)
24
 
, accounting for circadian tuning (if z 6= 0,h 6= 0) of equilib-
rium values for tissue thymidylate synthase (TS) activity S0 and liver dihydropyrimidine dehydrogenase (DPD)
maximal rate lDPD.
The variables represented are concentrations, either in blood, or in tissues, for:
P: plasma 5-FU, with source term a continuous infusion flow j(t), detoxicated at 80% in the liver by DPD
U : intracellular FdUMP (main intracellular active metabolite of 5-FU)
Q: plasma leucovorin, also known as folinic acid, with source term a continuous infusion flow k(t)
L: intracellular methylene tetrahydrofolate, active metabolite of leucovorin
N: nuclear activation factor of the ABC transporter MRP8 (ABCC11), assumed to be sensitive to damage to the
FdUMP target thymidilate synthase (TS)
A: ABC transporter activity (MRP8, or ABCC11, for 5-FU)
S: free thymidylate synthase (TS), with equilibrium value S0 (including circadian modulation if z 6= 0)
B: reversibly FdUMP-bound TS (binary complex U⇠T S)
T : irreversibly FdUMP-bound TS (stable ternary complex U⇠L⇠T S)
(B+T )/S: ratio of bound to unbound TS
The main features of this molecular PK-PD model are: active degradation of plasma 5-FU by dihydropyrimydine
dehydrogenase (DPD) in the liver, considered as a filter placed in the general circulation; active cellular intake
in the target tissue, together with active efflux by ABC transporter, of the active metabolite FdUMP of 5-FU;
stimulation of ABC transporter activity by nuclear factor, sensor of damage to drug target TS; reversible binding
of intracellular metabolite FdUMP to its target, forming a binary complex; irreversible binding of the same by
fixation of methylene tetrahydrofolate to the binary complex, yielding a stable ternary complex. A variant of this
model, where the nuclear factor inducing cell efflux was assumed to be directly triggered by the drug, which we
think physiologically less likely than by its intracellular effects on its target TS, has been published in [52]. When
circadian rhythms are considered relevant for PK-PD, peak phases jDPD and jT S for tuned values lDPD and S0
are fixed according to laboratory or clinical published data [71, 83], with adaptation from mice to Humans, as
mentioned in the previous Section.
A simulation of the model behaviour under square wave drug infusion flows of 5-FU and folinic acid following
a circadian rhythm is shown on Fig. 2.
2.3. Mutual exclusion from simultaneous infusions
Due to the chemical forms, always prepared for intravenous infusions (oxaliplatin is prepared as an acid solution
whereas 5-FU is usually presented in an alkaline form, hence a risk of precipitate in the infusion line), in which the
4
Jean Clairambault, Olivier Fercoq Combined anticancer drug delivery optimisation
FIGURE 2. Behaviour of the variables (concentrations in molecules) under a joint infusion in the
general circulation of 5-FU (P) and folinic acid (a. k. a. leucovorin, Q), mimicking a repeated
sequence of 4 consecutive days of chemotherapy followed by 10 days of recovery. The respec-
tive intracellular metabolites, U for FdUMP and L for methylene tetrahydrofolate (MTHF), act
synergistically, binding free thymidylate synthase, abbreviated in the sequel as TS (S), to form
firstly a reversible binary complex FdUMP⇠T S (B) and secondly an irreversible ternary complex
FdUMP⇠MT HF⇠T S (T ). The ABC transporter MRP8 activity (A) is stimulated by a nuclear
factor (N), itself triggered by bound TS. The last track shows the ratio of bound-to-unbound TS, a
measure of damages to TS. The parameters used in these simulations (see Section 4.4 for details)
have been chosen to produce expected effects, and have not been experimentally identified.
two drugs are available in the clinic, it is not advisable to deliver them simultaneously. This has led us to add mutual
exclusion terms for their infusion flows in the combined delivery to be optimised, as will be mentioned in Section
4. Rather than adding constraints on drug delivery schedules that are actually in use in the clic, we preferred, for
computing convenience, to represent the risk of precipitate formation by an added artificial “precipitate” variable
in the plasma, with supposed catastrophic consequences for toxicity to a healthy cell population:
dz
dt
(t) = k6.z(t)+ k5FULOHP.i(t). j(t),
resulting in a term dprec.z(t) to be added to the irrecoverable death rates di(t) and dkti(t) in the cell population
dynamic model (3.3) in Section 3.2, see below. This precipitation risk is systematically taken into account and
avoided at the infusion line level in chronotherapy delivery schedules [51, 64] and in the FOLFOX protocol [25].
2.4. Cytostatic drugs: control on cell cycle phase transitions
As regards cytostatic drugs, that have been named so because they slow down tissue proliferation but, contrasting
with cytotoxic drugs, do not - at least at low or medium doses - kill cells by damaging them and thus do not need
trigger repair mechanisms, we can represent their action as firstly proposed in [11] by inhibiting cell cycle phase
transition rates at G1/S and G2/M checkpoints. This representation is in particular adapted to cyclin-dependent
kinase inhibitors (CDKIs) that control these checkpoints. It may also be used to represent the action of growth
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factor receptor antagonists, that may be thought of as decreasing the boundary terms at the beginning of each cell
cycle phase, and also of anti-angiogenic drugs, that choke a solid tumour population, resulting in proliferating cell
population models for the division cycle in decreased boundary terms at the beginning of phases G1 and S. This
point will be made more precise in Section 3. We have already mentioned that oxaliplatin, a certainly cytotoxic
drug, can also be considered as having effects on phase transitions, as though it were additionally also a cytostatic
drug.
A way to represent control on the cell cycle by cytostatic drugs, for instance tyrosine kinase inhibitors (TKIs),
with introduction of a quiescent cell compartment, has been proposed in [37], using proliferative and quiescent cell
compartments. The equations are written as
8
>>>>>>>>>>>><
>>>>>>>>>>>>:
∂
∂ t
p(t,x)+
∂
∂x
p(t,x)+{µ(x)+b (x)} p(t,x) = 0 ,
p(t,x = 0) = 2(1  f )
Z
x 0
b (x ) p(t,x ) dx ,
p(0,x) = p0(x) ,
d
dt
Q(t) = 2 f
Z
x 0
b (x ) p(t,x ) dx  nQ(t) ,
Q(0) = Q0,
(2.3)
where p(t,x) is the density of proliferating cells of age x at time t, and Q(t) is the density of quiescent (i.e.,
non-proliferating, out of the division cycle) cells at time t, and the drug target here is f , rate of escape at mitosis
towards the siding phase G0 (quiescent cell compartment), this f to be enhanced by a cytostatic drug. The model
was identified on the human Non Small Cell Lung Cancer (NSCLC) cell line PC-9 submitted to the TKI drug
erlotinib.
In fact, the equation for the quiescent phase is just a linear equation and, rewriting the system for the proliferating
phase as
8
>>>><
>>>>:
∂
∂ t
p(t,x)+
∂
∂x
p(t,x)+(1  f )b (x)p(t,x)+{ f b (x)+µ(x)}p(t,x) = 0 ,
p(t,x = 0) = 2(1  f )
Z
x 0
b (x ) p(t,x ) dx ,
p(0,x) = p0(x) ,
(2.4)
we can see that it is nothing but the classical McKendrick transport equation ([62], see also [11], recalled in
Section (3.1)) for one proliferating phase with a balanced control between mitosis ((1  f )b ) and enhanced “cell
disappearance” ( f b +µ), i.e., way out of the proliferating phase towards either quiescence or death. In other cell
cycle models with phases G1,S,G2 and M [11], this representation of a target for cytostatic drugs should be placed
between phases G1 and S, resulting in a modification of the McKendrick equation :
8
>>>><
>>>>:
∂
∂ t
n1(t,x)+
∂
∂x
n1(t,x)+(1  f )K1!2(t,x)n1(t,x)+{ f K1!2(t,x)+d1(x)}n1(t,x) = 0 ,
n2(t,x = 0) = (1  f )
Z
x 0
K1!2(t,x ) n1(t,x ) dx ,
n2(0,x) = n2,0(x),
(2.5)
with the adjunction of a quiescent phase G0 represented by
8
<
:
d
dt
Q(t) = f
Z
x 0
K1!2(t,x ) n1(t,x ) dx  nQ(t) ,
Q(0) = Q0 ,
(2.6)
which is thus fed only by cells escaping from G1 instead of processing into S-phase.
In the sequel, we will focus only on the action of cytotoxic drugs oxaliplatin and 5-fluorouracil; nevertheless it
is also obviously possible to use this local representation of the dynamics of cytostatic drugs to study and optimise
combinations of both types of anticancer drugs, for instance oxaliplatin, 5-fluorouracil and cetuximab, as it is now
frequently the case in the clinic of metastatic colorectal cancer [13, 51].
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3. Cell cycle model with drug damage and repair phases
3.1. Age-structured models of the cell cycle in cell populations
Various models of the cell division cycle at the single cell level exist, some of them with remarkable descriptions
of their molecular mechanisms, allowing to study entrainment of the cell cycle by the circadian clock based on up-
to-date physiological knowledge [40–42,44], but they are not adapted to describe proliferation in cell populations,
except by considering cellular automata, as in [1–4]. To the aim of describing proliferation in tissues, we rather
advocate age-structured partial differential equations (PDEs), that take into account the main source of variability
in such proliferating cell populations, i.e., age in the division cycle. We recall here the McKendrick [62] (or Von
Foerster-McKendrick) model for the cell division cycle in proliferating cell populations [11, 19–24, 67], where
ni(x, t) is the density of cells in cell cycle phase i of age x at time t:
8
>>>>>><
>>>>>>:
∂ni(t,x)
∂ t
+
∂ni(t,x)
∂x
+di(t,x)ni(t,x)+Ki!i+1(t,x)ni(t,x) = 0,
ni+1(t,0) =
Z •
0
Ki!i+1(t,x)ni(t,x)dx,
n1(t,0) = 2
Z •
0
KI!1(t,x)nI(t,x)dx.
(3.1)
together with an initial condition (ni(t = 0, .))1iI . It may be shown [67] that for constant or time-periodic control
on the di and Ki!i+1, solutions to (3.1) satisfy ni(t,x) ⇠ C0Ni(t,x)el t , where C0 is a real positive number and Ni
are eigenvectors of the eigenvalue problem
8
>>>>>>>>>><
>>>>>>>>>>:
∂Ni(t,x)
∂ t
+
∂Ni(t,x)
∂x
+
 
l +di(t,x)+Ki!i+1(t,x)
 
Ni(t,x) = 0,
Ni+1(t,0) =
Z •
0
Ki!i+1(t,x)Ni(t,x)dx,
N1(t,0) = 2
Z •
0
KI!1(t,x)NI(t,x)dx,
Ni > 0, Â
i
Z T
0
Z •
0
Ni(t,x)dxdt = 1.
(3.2)
The importance of the first eigenvalue l , which, provided that the system is growing, is positive and simple [67],
and obviously governs (since the positive eigenvectors Ni are bounded) the time-asymptotic behaviour of the cell
populations ni(t,x) in each phase i, is thus fundamental, and it may be studied as a resulting observable, a function
of the theoretical drug control conditions exerted onto the system. This has been done in [8–11].
In this system of transport equations, one for each phase i of the cell division cycle, the control on phase
transition rates Ki!i+1(t,x)(i = 1,2) may be decomposed in ki(x).yi(t), using an experimentally identified step-
like function ki of age x [11] and a theoretical 24-hour periodic function yi of time t.The phase difference between
y1 and y2 is set to a half-period (12 hours) because of the known phase opposition between the clock-controlled
proteins Wee1 and p21 [43, 61], which themselves control Cdk1 (that determines the G2/M transition) and Cdk2
(that determines the G1/S transition), respectively. Another (numerical) reason is that, as mentioned in [11], this
phase difference has been found to maximise the growth coefficient, first eigenvalue of the periodically controlled
McKendrick system; otherwise said, this value of a half-period for the phase difference between y1 and y2 yields
the lowest population doubling time. Note that whereas in the PK-PD model circadian clocks are optional, in the
cell cycle model they are fundamental to make the difference between healthy and cancer cell populations, as
presented in Section 4.1.
3.2. A new cell cycle model with repair
In the sequel, we propose a more elaborate model, starting from the previous ones, for the cell population model
under insult by drugs, taking into account various modes of action of cytotoxic drugs on the cell cycle, and knowing
that the parameters of this model are many and will take many efforts to be experimentally identified. Nevertheless,
we present it as a possible proof of concept for therapeutic optimisation procedures, based on representations that
are partly molecular (for intracellular drug effects) and partly phenomenological (for the cell cycle), but always
physiologically based, after our knowledge of the mechanisms that govern progression in the cell division cycle.
7
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The proposed model, a variation of the previous McKendrick-like models for the division cycle in cell popula-
tions mentioned above, runs as follows
8
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>:
• ∂
∂ t
n1(t,x)+
∂
∂x
n1(t,x)+
 
K1(t,x)+L1(t)+dkt1(t)
 
n1(t,x)  e1r1(t,x) = 0 ,
∂
∂ t
r1(t,x)+
 
d
kt1(t)+ e1
 
r1(t,x) L1(t)n1(t,x) = 0 ,
n1(t,x = 0) = 2n3(xM, t) ,n1(0,x) = n1(x), r1(0,x) = r1(x) ,
with L1(t) =C1
F0  F(t)
F0
, d
kt1(t) = D1
✓
F0  F(t)
F0
◆2
,
and K1(t,x) = k1(x).y1(t,x) ,
• ∂
∂ t
n2(t,x)+
∂
∂x
n2(t,x)+
 
K2(t,x)+L2(t)+dkt2(t)
 
n2(t,x)  e2r2(t,x) = 0 ,
∂
∂ t
r2(t,x)+
 
d
kt2(t) + e2
 
r2(t,x) {L2(t)+L02(t)}n2(t,x) = 0 ,
n2(t,x = 0) =
Z
x 0
K1(t,x )n1(x , t) dx , n2(0,x) = n2(x) , r2(0,x) = r2(x) ,
with L2(t) =C2
F0  F(t)
F0
, L02(t) =C
0
2
S0  S(t)
S0
,
d
kt2(t) = D2
✓
F0  F(t)
F0
◆2
+D02
✓
S0  S(t)
S0
◆2
,
andK2(t,x) = k2(x).y2(t) ,
• ∂
∂ t
n3(t,x)+
∂
∂x
n3(t,x)+M.1l[xM ,+•[(x) n3(t,x) = 0 ,
n3(t,x = 0) =
Z
x 0
K2(t,x )n2(t,x ) dx , n3(0,x) = n3(x) .
(3.3)
In this cell cycle model, 5 cell subpopulations are represented by their density variables: ni(i = 1,2,3) for age-
structured phases G1, S  G2 and M, respectively, plus ri(i = 1,2) for supplementary repair phases R1 and R2
(in which age is unchanged) corresponding to cells subject to DNA damage occurring in phases G1 and S G2
respectively. The durations of phases G1, S G2, R1 and R2 are not fixed (no upper bound in age, although in fact,
they will never last infinitely long), whereas M-phase is assumed to have fixed duration (e.g., xM =1 hour) and to
always (just by setting high the value of the constant M in the last equation, sending all cells to division at age xM
in M-phase) lead in such fixed time each cell in mitosis into 2 intact daughter cells in G1. We assume that cells
in M-phase are endowed with a supercoiled DNA, which make them unreachable by DNA-targeted drug insults,
and we have not considered here the effects of M-phase-specific drugs (vinca alkaloids or taxanes); it is certainly
possible to represent them by targets at the M/G1 transition (i.e., by blocking mitosis), but thus far, the M-phase is
free from pharmacodynamic effects in this model.
As regards the two cytotoxic drugs at stake in this study, apart from this last point about M-phase, oxaliplatin
is a non phase-specific cytotoxic drug, whereas 5-FU is S-phase specific. Functions Li(t) quantify the effect of
oxaliplatin (and of 5-FU for S G2) on the cell subpopulation under attack in G1 (i = 1) and S G2 (i = 2) that
can be coped with by repair, whereas d
kti(t) functions stand for the cytotoxic effects of oxaliplatin that cannot be
repaired (one can think of them as double-stranded breaks in the DNA [31]), be they occurring in G1, R1, S G2
or R2. Note that we have not considered in our simulations (see Sections 3.2 and 4.4, where D02 = 0) irrecoverable
effects of 5-FU in our cell population model for the division cycle, assuming that its main target is apoptosis
induced in S-phase, probably due to lack of thymine [36], but that these effects are amenable to repair. We do
not consider in this model the intra-S checkpoint. Thus functions Li(t) and dkti(t) together represent the ultimate
pharmacodynamics of cytotoxic drugs on their actual targets: the cell division cycle.
In each repair phase Ri, fed from either G1 or S G2 by the corresponding “leak” function Li, damaged cells
with density ri(t,x), keeping their age x unchanged, undergo a repair mechanism represented by a time constant
e
 1
i . Those cells that have been successfully repaired move back to the corresponding normal cycle phase, G1 or
S G2, and having become normal cells (ni) again, are candidates to proceed to next phase at the corresponding
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FIGURE 3. Sketched linear model of the cell division cycle in proliferating cell populations.
Variables ni(t,x) are densities of cells at time t and age in phase x in subpopulations, i.e., cell
cycle phases G1 (i = 1), S G2 (i = 2) and M (i = 3). Moreover, two additional subpopulations
have been added, R1 and R2, with age-independent variables r1(t) and r2(t), respectively, to
describe the fate of those cells that have been hit by drug-induced DNA damage and are waiting
to be repaired - or sent to apoptosis - before being able to join next phase at G1/S and G2/M
checkpoints, respectively.
checkpoint, which is controlled by functions k(x).yi(t) (multiplied or not by cytostatic drug pharmacodynamics
(1  g
ks i(t)), see below). At the same time, a more destructive cytotoxic death process represented by functions
d
kti(t) goes on, and is enhanced by more extended DNA damage, which is represented by a nonlinear effect as a
function of DNA damage for functions d
kti(t), that are tuned according to the cytotoxic drug at stake.
We consider here that repair in phase Ri consists only in a loss of time e 1i , that does not depend on the drug
dose ; however, the drug dose does influence the instantaneous rate Li(t) of cells sent to repair. A simplifying
assumption made is that repair is always performed ad integrum, i.e., we have not considered here the possibility
to represent errors in repair that may contribute, together with inefficient control of DNA at cell cycle checkpoints,
to the known genomic diversity and instability, let alone aneuploidy, of cancer cell populations. Moreover, the
checkpoints in this model represent cell cycle arrest by cumulative effects of oxaliplatin seen as sending cells to
the repair phase, this drug having been reported to act more by arrest at transitions than by induction of apoptosis
[81, 82].
Normal transition rates (in the absence of damage to the cell), K1(t,x) at G1/S and K2(t,x) at G2/M are de-
scribed in a multiplicative way by ki(x), the physiological transition rate in the absence of circadian control (de-
termined by the distribution of cell cycle phase durations in the cell population, as shown in [11]), multiplied by
yi(t), which represents circadian gating by p21 at G1/S and by Wee1 at G2/M [43, 61]. Thus physiologically, as
already mentioned in Section (3.1),
Ki(t,x) = ki(x).yi(t) .
Additional cytostatic drugs, e.g. growth factor inhibitors, cyclin-dependent kinase inhibitors (CDKIs), or even
antiangiogenic drugs, may be represented in this model for a cancer cell population by an inhibitory effect on G1-
phase by choking boundary terms at cell cycle transitions M/G1 or G1/S. Indeed, since these drugs are assumed
to be non-cytotoxic, taking into account their effect should be done not on death terms, but only on the boundary
terms, either n1(t,x = 0) or n2(t,x = 0), i.e., in the latter case on k1(x).y1(t) by a multiplication by (1 gks1(t)),
where g
ks1(t) stands for the pharmacodynamics of such cytostatic drugs (of maximum value 1). This may be
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FIGURE 4. Pattern of the nonzero elements of the transition matrix of the discretised dynamics.
Each block represents the transitions from one phase to the other. The block G1/G1 is a subdiag-
onal matrix representing the fact that at each time step, the cells that have stayed in G1 get older.
The block R1/R1 is a diagonal matrix that represents cell proliferation arrest until cells go back
to G1-phase .
achieved by the adjunction of a quiescent phase, as in equation (2.3), that has been studied in detail with parameter
identification on cell cultures in [37], using in our case the suggested modifications (2.5, 2.6) of the system. Note
that another possible way of representing the action of cytostatics is by slowing down a non constant velocity factor
dx
dt of cell progression in G1 introduced in the argument of the
∂
∂x operator, as proposed in [45].
3.3. Discretisation scheme for the cell population dynamics model
To perform numerical simulations, we discretised the PDE model (3.3). We adapted the discretisation scheme
presented in [11], Section 3.3 by adding repair phases, transitions from the physiological phases towards these new
phases and permanent transitions from these new phases towards the physiological phases. The number of cells in
the discretised model is represented by nk, ji = ni(kD t, jDx) and the dynamics of this discretized variable is given
for the time step k by nk+1 =Mknk, where nk is the concatenation according to ages j and phases i of the nk, ji s. The
matrix Mk is a block matrix, where each block represents transitions from one phase to the other. The size of each
block is related to the duration of the corresponding phase. For instance, we fixed the duration of mitosis to one
hour, so that we do not need to consider ages larger than one hour in M-phase. We give in Figure 4 the position of
the nonzero elements for a given matrix Mk.
The coefficients of the PDE model depend on the drug infusion schemes. The coefficients of the transition
matrices Mk will also depend on them accordingly.
4. Therapeutic optimisation
4.1. Optimal long term viable chemotherapy infusion schedules
Focusing on cancer chemotherapy, we propose to minimise the growth rate of the cancer cell population while
maintaining the growth rate of the healthy cell population above a given toxicity threshold L (we chose in the ap-
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FIGURE 5. Gating at cell cycle phase transitions due to circadian clock control. Functions yHi
(left, healthy) and yCi (right, cancerous) define the hours at which the cells of each population
(healthy and cancerous) can change phase: when y(t) = 0, transition gates are closed. The dash-
dotted lines correspond to the transition from G1 to S G2 and the solid lines correspond to the
transition from S G2 to M. In the model presented here, healthy and cancerous cells differ only
by their responses to circadian clock control, represented by functions yHi and y
C
i .
plication presented below L = 0.021h 1). Infusions here should be thought of as referring to the drugs Leucovorin,
5-FluoroUracil (5-FU) and oxaliplatin (lOHP) as explained in Section 2.
We consider two cell populations with their respective dynamics. We model both of them using the same age-
structured cell population dynamics model (3.3) but with different parameters. In fact, we assume that the tran-
sition and death rates are the same when there is no circadian control, but that cancer cell populations show a
looser response to physiological circadian control. More precisely, we model this phenomenon by different time-
dependencies for gating at transitions in (3.4). For healthy cells, we set KHi (t,x) = ki(x).y
H
i (t) and for cancer cells,
we set KCi (t,x) = ki(x).y
C
i (t) where y
H
i (t) and y
C
i (t) are given, similarly to the ones in [11], by
y
H
1 (t) = cos
2(2p(t  10)/12)1l[7;13](t)+ e,
y
H
2 (t) = cos
2(2p(t  22)/12)1l[19;24[[[0;1](t)+ e,
y
H
3 (t) = 1,
y
C
1 (t) =
5
8
cos2(2p(t  10)/12)1l[7;10](t)+
5
8
cos2(2p(t  10)/3)1l[10;22](t)+ e,
y
C
2 (t) =
5
8
cos2(2p(t  22)/12)1l[19;22](t)+
5
8
cos2(2p(t  22)/3)1l[22;24[[[0;10](t)+ e,
y
C
3 (t) = 1,
recalling from [11] that e is here a very small positive number (typically 10 10) put in the equations only to ensure
y
H
i > 0 and y
C
i > 0, which may be shown as sufficient to imply irreducibility of the matrix M in numerical
simulations (see below) and thus applicability of the Perron-Frobenius theory.
We assume that the drug has the same effect on both populations, i.e. L1(t), L2(t) and that death rates are the
same. This modelling choice couples the behaviours of the populations through the drug infusions.
Then we represent the growth rates of both populations by the Floquet eigenvalue of the corresponding model
(lC for cancer cells and lH for healthy cells). We shall search for an optimal drug infusion schedule among the set
of measurable and bounded (classical assumptions in control theory [70] for instance) and T -periodic functions.
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We obtain the following Floquet eigenvalue optimisation problem with constraints:
min
g(·)
lC(g)
lH(g)  L (4.1)
g T -periodic, mesurable and bounded
4.2. 24h-periodic drug infusions
The McKendrick population dynamics yields a cell population described by the number of cells ni(t,x), where i is
the phase, t is the time and x is the age in the phase. As seen in Section 3.1, if the death and transition rates di and
Ki!i+1 are T -periodic, then the solutions ni(t,x) to (3.1) are asymptotically - i.e., for large time t - equivalent (in
a L1 sense that can be made very precise [67]) to C0Ni(t,x)el t , where the eigenvector Ni is T -periodic in the time
variable.
Hence, searching for infusion strategies that optimise the Floquet eigenvalue of a biological system is a way to
study its long term behaviour under drug infusion. Indeed, most of chemotherapy schedules are repeated until the
patient responds to the treatment, and conversely stopped if the patient does not respond after a given number of
chemotherapy courses. In this model, we take into account this periodic behaviour directly in the model and in our
objective function.
Classically, chemotherapy schedules consist of several days of severe treatment followed by a longer duration of
rest (2 days of treatment every other week for FOLFOX therapy [25], 4 days of treatment every other week or even
5 days of treatment every third week for chronotherapy [64]). We chose, instead of imposing a rest period, to add a
toxicity constraint that imposes in a dynamic way that the growth rate of the healthy cell population always remains
high enough for the patient to live with a reasonable quality of life, even though he may experience drug-induced
diminished physiological functions. In order to be compatible with the periodicity of physiological circadian con-
trol, the periodicity of the treatment should be a multiple of 24h. Numerical tests that we have performed on our
model show that a period of one day seems to be a good choice, because other locally optimal solutions that we
found assuming longer periods finally proved to be all 24h-periodic.
But since we have coupled the population dynamics with the PK-PD model described in Section 2, we have
to take care that periodic infusion of drugs in the same way results (asymptotically) in periodic transition and
death rates in the population dynamics model. In the case of linear systems, the Floquet-Lyapunov theory (see
[63] for instance) gives the following condition: if the eigenvalues of the so called monodromy matrix (also called
Floquet multipliers) all have modulus smaller than 1, then the system is asymptotically stable, and a periodic input
asymptotically results in a periodic output.
One can generalise this result to a T -periodic nonlinear system. For a given T -periodic control u let F be the
map that to an initial state y0 associates the state yT of the system at time T . If F is a contraction in the sense
that there exists c < 1 such that for all initial states y0 and z0, kF(y0) F(z0)k = kyT   zTk  cky0   z0k, then a
periodic input asymptotically results in a periodic output. We numerically checked this fact during computations.
4.3. Optimisation procedure
Our goal, formalised in (4.1), is to minimise the growth rate of the cancer cell population while maintaining the
growth rate of the healthy cell population above a given toxicity threshold L . To obtain the numerical resolution
of problem (4.1), we firstly discretise the PK-PD models (2.2) and (2.1) and the population dynamics model (3.3).
This is the so-called direct method, which consists of a total discretisation of the control problem and then of
solving the finite dimensional optimisation problem obtained.
In our setting, at each time, the control gl(t) is the flow of drug l (1  l  ndrugs) infused at time t. Here,
ndrugs = 3 for 5-FluoroUracil, leucovorin and oxaliplatin. The discretised control (gkl )l,k will be the array of the
infusion time step by time step and drug by drug. As we search for 24h-periodic controls with one drug, we only
need to define g on one day, i.e. g 2 Rndrugs⇥NT , where NT = T/D t is the number of time steps.
We need to bound the flow of each drug to avoid evident toxicity. We bounded the flow of 5-FU and leucovorin
to ḡ1 = ḡ2 = 500 mg/m2/h and the flow of oxaliplatin to ḡ3 = 50 mg/m2/h. Hence, g 2 G = [0; ḡ1]NT ⇥ [0; ḡ2]NT ⇥
[0; ḡ3]NT .
Given a discretised infusion strategy g, we build the matrices MC(g) and MH(g), that are the nonnegative ma-
trices modelling the discretised dynamics of each cell population under drug infusion g when drug concentrations
represented by the PK-PD models have reached their day-periodic asymptotic behaviour.
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Thus, we study the optimisation of the growth rate in the discretised model, represented by the principal eigen-
value r of the nonnegative matrices MC for cancer cells and MH for healthy cells where MH = MNTH . . .M1H is
given in Section 3.3 (see also [11], Section 3.3) and MC is defined accordingly. The discretised approximation of
lC(g(·)) is then 1T log
 
r(MC(g))
 
, and 1T log
 
r(MH(g))
 
for lH(g(·)). We obtain the finite dimensional optimi-
sation problem:
min
g2G
1
T
log
 
r(MC(g))
 
(4.2)
1
T
log
 
r(MH(g))
 
  L
We chose a discretisation step of 10 minutes because it may be considered as a lower limit to the half-life
time of 5-FU and oxaliplatin in the plasma [12, 26, 68], which is most likely even lower than the half-time of its
downstream molecular effects at the cell level, our concern here. The oldest ages represented in the discretisation
scheme are 10 days for each phase except for mitosis (M-phase) where we choose 2h.
By the Perron-Frobenius theorem [6], we know that if M is nonnegative and irreducible, its principal eigenvalue
r(M) is positive and is a simple eigenvalue. Moreover, the principal eigenvector is unique up to normalisation and
can be chosen such that u(M)  0. In our setting (irreducibility of the matrix and the Perron-Frobenius theorem),
one can naturally define a function r from the set of nonnegative and irreducible real matrices in Rn into R+, that
to a matrix associates its principal eigenvalue.
General eigenvalue optimisation of non symmetric matrices is a difficult (non convex, non differentiable) prob-
lem: see [54] and [66] for two algorithms dealing with this problem. However, for nonnegative irreducible matrices,
as the principal eigenvalue is simple, this implies that r is differentiable. Indeed, denoting by v and u the left and
right eigenvectors of a matrix M associated with a simple eigenvalue r , the derivative of r at M can be written as
[46]:
∂r
∂Mi j
= viu j (4.3)
Thus, as the objective function is differentiable, differentiable optimisation theory applies. We then get the
complete gradient of the objective by the chain rule. We have a composite objective of the type
f (g) =
1
T
log r  MH  L(g) ,
where r is the principal eigenvalue, MH is the discretised population dynamics, L is the output of the discretised
PK-PD and g is the discrete periodic control. To compute the gradient of the objective function, we thus compute
the derivatives of all these functions, either in closed form (for log and MH ) or by an iterative algorithm (for r and
L(g)) and we multiply them all up. Following [32], we set the stopping criterion of internal iterative algorithms
according to the theory of consistent approximation [69].
To solve the non convex problem (4.2), we use the method of multipliers [7], which solves a sequence of non
constrained optimisation problems whose solutions converge to a local optimum of the constrained problem (4.2).
4.4. Simulations
We coded the discretised versions of the PK-PD models (Section 2) and of the population dynamics model (Section
3.2), and the method of multipliers [7] in Scilab [76].
We chose the following constants in our model. Recall that most of them were not experimentally identified.
– Oxaliplatin PK-PD model: xLOHP = 5, cl = 4, l = 0.5, VLOHP = 100, µK = 0.01, K0,BASE = 4, jPLP = 8h, e = 0.1,
VGST = 200, KGST = 1, kDNA = 1, µF = 0.25, Fo = 10, µG = 0.01, G0,BASE = 0.8, d = 0.1, jGSH = 20h.
– 5-FU and Leucovorin PK-PD model: k0 = 0.1, a = 5, b = 1, lDPD,BASE = 5, jDPD = 23h, h = 0.5, mDPD = 0.5, W
= 100, x5FU = 4.4, c = 0.01, d = 1, k1 = 0.2, k 1 = 0.04, k2 = 0.5, V = 450, k3 = 0.1, k4 = 1, kN = 0.01, S0,BASE =
1, z = 0, jT S = 11h, n = 2, l = 1, µN = 0.1, µA = 0.1, µT S = 0.5, vT = 0.025.
– Exclusion constraint: k6 = 2, k5FULOHP = 0.0001, dprec = 100.
– Population dynamics model: e1 = 0.01h 1, C1 = 0.1, D1 = 10, e2 = 0.01h 1, C2 = 1, C02 = 1, D2 = 10, D
0
2 = 0, M
= 1000, xM = 1h.
y1(t,x) and y2(t) are given in Subsection 4.1 for healthy and cancerous cell populations. For k1(x) and k2(x),
we took the functions identified in [11], i.e.
ki(x) =
ji(x)
1 
R x
0 ji(x )dx
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FIGURE 6. Locally optimal infusion strategy with a combination of leucovorin (dash-dotted
line), 5-FU (dashed line) and oxaliplatin (solid line). These infusions are repeated every day in
order to minimise the growth rate of the cancer cell population while maintaining the growth rate
of the healthy cell population above the toxicity threshold of 0.021h 1.
where ji is the probability density function of a Gamma law given by
ji(x) =
1
G (ai)
(x  gi)ai 1b aii e
 bi(x gi)1l[gi;+•[(x) i = 1,2,
G is the gamma function, a1 = 8.28, b1 = 1.052h 1, g1 = 0h, a2 = 3.42, b2 = 1.47h 1, g2 = 6.75h (we
substracted the fixed duration of 1 hour for the mitosis phase M from the duration of S G2  M identified
in [11], thus obtaining for j2 an estimate of the probability density function of the duration of S G2, so that
the index i = 2 actually stands for the G2/M transition).
At the end of the optimisation algorithm, we obtained a locally optimal solution for the discretised optimisation
problem (4.2) and we reported it in Figure 6.
It consists of infusing the three drugs in the following order: leucovorin between 10 h 30 and 21 h 20 (stopping
the infusion at 19 h in oder to avoid mixing medicines has a marginal impact on the performances), 5-FU between
19 and 20 h and finally oxaliplatin between 20 and 22 h at maximal flow. Then, these infusions are repeated every
day until the situation justifies to stop the treatment.
Note that if we keep the circadian clock response differences between healthy and tumour populations, as illus-
trated on Figure 4.1, essential to define the behaviours of the two populations in our model, but forsake circadian
control on the pharmacology of the drugs, we obtain a very close result, as illustrated on Figure 4.4. This point will
be discussed in the conclusion.
Without drug infusion, the growth rate of cancer cells (0.0265h 1) is larger that the one of healthy cells
(0.0234h 1), this difference being due to different responses to circadian clock control. This gives an evolution
of the respective populations, cancer cells becoming more and more present: see Figure 8. By following the infu-
sion strategy numerically determined by the optimisation algorithm, we obtained that the asymptotic growth rate
in the healthy cell population was actually above the chosen toxicity threshold (lhealthy   L = 0.021h 1) and that
the asymptotic growth rate of cancer cells was weakened to (0.0229h 1). Thus by this optimal infusion strategy,
the asymptotic growth rate for cancer cells was reduced by 13.3 % while the growth rate for healthy cells was
reduced by only 10.0 %, so that the toxicity constraint is satisfied. This gave us a description of the evolution of
the respective populations, which is illustrated on Figure 9.
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FIGURE 7. The same optimal strategy as in Figure 6, here in the absence of circadian control on
the molecular PK-PD model. Locally optimal infusion strategy with a combination of leucovorin
(dash-dotted line), 5-FU (dashed line) and oxaliplatin (solid line). These infusions are repeated
every day in order to minimise the growth rate of the cancer cell population while maintaining the
growth rate of the healthy cell population above the toxicity threshold of 0.021h 1. One sees that
differences from Figure 6 are hardly perceptible, showing a limited impact of circadian chrono-
PK-PD and conversely stressing the major importance of circadian physiological control on the
cell cycle as regards differences between healthy and cancer cell populations in our model.
These infusions cause possibly recoverable damage to the cells (be they healthy or cancerous), sending them to
repair, at a rate L1(t) in G1-phase and at a rate L2(t) in phase S G2 (see Figure 10).
If we compare L2(t) (Figure 10) and the fraction of the cell populations in phase S G2 (Figure 11), we can
see that the best time to cause damage in phase S G2 is when the proportion of cancer cells is significantly larger
than the proportion of healthy cells in this phase, i.e., between 22 and 24 h. The strategy takes into account the
delay between the infusion and the effective action of the drug at the cell level due to the pharmacokinetics and the
pharmacodynamics (diffusion, metabolism and elimination) of the drugs. We may also remark that although the
infusion strategy stops infusions for 13 hours per day, the drugs remain active all day long.
In our cell population dynamics model, the fraction of cancer cells in G1-phase is never significantly higher
than the fraction of healthy cells in G1-phase, so that we cannot tune a significant difference between the two
populations in G1, and L1(t) should remain small to limit the toxicity of the treatment. Hence, 5-FU, that causes
little damage to cells in G1-phase, is the main drug in this infusion strategy.
Simulating the transition from the stationary state without drug to the stationary state with periodic drug
infusion (Figure 12), we see that after a transition of around 10 days, the treatment performs as expected
(lcancer = 0.0229h 1 and lhealthy = 0.021h 1). As mentioned above, by this optimal infusion strategy, the asymp-
totic growth rate for cancer cells was reduced by 13.3 %, whereas the asymptotic growth rate for healthy cells
was reduced by only 10.0 %, and the toxicity constraint lhealthy   L = 0.021h 1 was satisfied. Note also that the
growth rate in the healthy cell population always remains positive, which means that the healthy cell population
production never decreases. This does not mean that there is no negative drug effect on this healthy cell popula-
tion: one should have in mind that we have represented here only the rate of production of healthy cells, e.g., in
the gut or in the bone marrow, while for obvious homeostatic reasons, constant consumption (elimination in the
intestinal lumen, or release in the general blood circulation) must be considered and should result here, together
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FIGURE 8. Evolution of the population of cancer (blue, above) and healthy (green, beneath) cells
without drug infusion during 12 days. We can see that the populations have different exponential
growth rates (lcancer = 0.0265h 1 and lhealthy = 0.0234h 1). Cancer cells proliferate faster than
healthy cells.
with this decrease of production, in a decay in physiologically functional healthy cell population (in our example,
mature villi enterocytes or mature blood cells). However, since the growth rate in the healthy cell population never
becomes negative, the source of healthy cell production is preserved by the optimisation procedure.
The proposed infusion strategy combines the three drugs. This means that we obtain better results in terms of
the trade-off between damage to cancer cells and toxicity to healthy cells by infusing smaller doses of each drug
than a larger dose of one single dose. This confirms (once more) that the use of this combination is efficient for the
fight against cancer. We shall remark however that the proposed strategy is different from the ones used today in
the clinic.
Firstly, the optimisation algorithm yields a daily schedule consisting of infusions during 11 hours and rest
periods of 13 hours whereas one usually infuses larger doses and then gives longer rest periods to the patient. As
discussed in Subsection 4.2, the schedules that seem to take the best advantage from the influence of circadian
clocks on the proliferation of cells have a period of one day. However in this work, we did not study the emergence
of drug resistances among the cancer cell population, although resistance is one of the main causes of the failure of
chemotherapies in the long term. One may wonder here whether resistances are more or less likely to appear when
performing short, rather than long, rest periods.
Secondly, the locally optimal strategy returned by the optimisation algorithm suggests infusing oxaliplatin after
5-FU. In the FOLFOX schedule for instance [25], it is advised to infuse oxaliplatin before 5-FU. However, in [35],
the authors show that infusing oxaliplatin before, during or after the exposure to 5-FU does not produce significant
differences. The results of the optimisation procedure performed on our preliminary model (in which parameters
have not been experimentally identified) suggest that infusing oxaliplatin after 5-FU may have some advantages.
5. Conclusion and future prospects
We have presented in this study what is to our best knowledge the first physiologically based model of action of
a combination of cytotoxic drugs, commonly used in the clinic of colorectal cancer, on the division cycle - with
consideration of the two main phase transition checkpoints G1/S and G2/M - in populations of cells, together
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FIGURE 9. Evolution of the population of cancer (blue, above) and healthy (green, beneath) cells
with the drug infusion, starting at time 0, given by the algorithm. Healthy cells keep multiplying
(lhealthy = 0.021h 1) while the cancer cell population is weakened (lcancer = 0.0229h 1).
FIGURE 10. Transition rate to repair phases R1 and R2 under the locally optimal infusion strat-
egy presented in Figure 6. The L1(t) and L2(t) entries in the population dynamics model (3.3)
represent the (recoverable) damage on cells induced by the drug infusions.
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FIGURE 11. Fraction of the cancer cell population in phase S G2 (solid line) among all cancer
cells and fraction of healthy cell population in phase S G2 (dotted line) among all healthy cells.
FIGURE 12. Daily mean growth rates for cancer (solid line) and healthy cells (dashed line)
when starting drug infusions at time 0. After a 10-day transitional phase, the biological system
stabilises towards the expected asymptotic growth rate.
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with the use of numerical optimisation algorithms to meet the question of maximising tumour cell kill under the
constraint of preserving healthy cell population from unwanted toxic side effects.
The molecular PK-PD models are based on physiological knowledge, can evolve with new findings in this area
and their parameters - that are thus far only theoretical, tuned to produce observable effects on their molecular
targets - should be identified, at least partly, by biological experiments led in collaboration with teams of pharma-
cologists. Obviously enough, these models are quite complex, and some of their features (e.g., ABC transporters
for 5-FU) may be forsaken if they are not proven to be important, in order to simplify experimental identification
of model parameters. So far, these PK-PD models should be only considered as providing biological bases for a
proof of concept of therapeutic control optimisation on the cell population dynamic model for proliferation.
This cell population dynamic model is a new version of a system of McKendrick-like equations, the charac-
teristics of which must be adapted to represent either cancer or healthy cell populations. In this setting, we have
chosen, as we had done previously [9–11], to use the chronotherapeutic paradigm, in which healthy and cancer cell
populations differ only by good or bad circadian clock control on cycle phase transitions. This should indicate new
tracks to optimise cancer chronotherapeutic schedules, when the classic drugs oxaliplatin and 5-FU are combined
with other drugs, in particular with irinotecan and cetuximab [51].
Also of note, since the model relies on physiological principles, it is possible, when chronotherapeutics has
not proved useful (which may be due to persistence of good circadian clock control in tumours, or to bad and
unrecoverable control by the central circadian pacemaker of the suprachiasmatic nuclei on the whole organism,
impinging also healthy cell populations) to use other pathological differences in cancer cell populations, compared
with healthy tissues. For instance, adding to this model a physiological representation of the control by the p53
protein of phase transitions, DNA repair or apoptosis launching, based on triggering of the ATM protein by DNA
damage and subsequent launching of p53 oscillations (as presented in [27–30,60]) should prove useful. Indeed, it is
known that p53 is mutated and inefficient in about 50% of solid tumours [77], and thus instead of circadian control,
it is possible to use impaired - or not - p53 control to account for differences between the two cell populations.
Another expected benefit of the adjunction of a DNA damage-ATM-p53 model should be to assess the respective
roles in cell death and in cell cycle phase transition blockade of the drug oxaliplatin, assumed to act by enhancing
cell death but also, and primarily, according to [81, 82], by blocking G1/S and G2/M phase transitions.
Another valuable remark about the essential physiolological (or physiopathological) difference in responses
to circadian clock stimuli between healthy an cancer cell populations is that it may be related to a poor quality of
intercellular communications in the latter. Indeed, it has been proposed for a long time, and recently updated by the
same author [79, 80], that impaired gap junctions in cancer cells are a constantly observed phenomenon that may
account for the specificity - in particular heterogeneity - of cancer cell populations. In our model, as illustrated on
Figure 4.1, the extended support of the cancer gating function yC, with a long tail, compared to the much sharper
healthy gating function yH , may perfectly be considered to account for such poor synchronisation between cells in
the cancer cell population due to their impaired gap junctions, and possibly to other biophysical mechanisms such
as impaired mitochondria, as mentioned in [14]. In this respect, response to circadian clock stimuli at transitions
between cell cycle phases is essential in our model, but circadian chronopharmacology of anticancer drugs is not.
Obviously also, to theoretically investigate optimisation of therapeutic procedures using new drugs that are
known by their action on physiological targets to hit cancer cell, and not, or less, healthy cell populations, is
another possible application of this way of representing pharmacodynamic effects of anticancer drugs. It requires
a PK-PD model for each drug, but the target cell population dynamic model of proliferation can be based on
the same principles, and the optimisation procedure can be strictly the same. Note also that we have chosen to
optimise eigenvalues, since the population model is linear. If a linear model proves inadequate, it is also possible to
dynamically optimise therapeutics using cell population numbers, as done in [5, 16], using the same optimisation
principles, but not Perron-Frobenius-Floquet theory. For theoretical methods in optimal control applied to cancer
therapeutics in a more general setting, we refer to the book [75] and to its foregoer [74].
Finally, one must note that in the present representation, healthy and cancer cell populations are considered
as evolving separately, without any population coupling effect between them, except by drugs. The question of
evolution toward drug resistance, in particular, and optimisation of therapeutics to circumvent it (see a review
in [14]), has led to rather different models of cell populations evolving according to a resistance phenotype, in
the framework of cell Darwinism, advocated, e.g., in [38, 39] and recently studied from a deterministic point of
view by integro-differential equations in [15, 57–59, 72]. In these models, coupling between cell populations is
present, representing competition between cells for space and nutrients by a nonlocal logistic term (in a Lotka-
Volterra-like setting) in the global - cancer and healthy - cell population. These models are amenable to describe
evolution towards drug resistance of a phenotype representing between-cell variability in the cancer cell population.
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Whether it is possible and relevant to address in the same model such phenotype evolution towards drug resistance
and circadian modulation on proliferation - two phenomena that do not occur at the same time scale, and not
necessarily independently, as the same disorganising mechanisms, present in cancer, that trigger heterogeneity and
drug resistance in cancer cell populations (also reviewed in [14]) may also trigger the disruption of circadian clocks
- or the cancer tissue response to circadian inputs - is still an open question.
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